Parent-Child EF Intervention
Launched by KORONIS BIOMEDICAL TECHNOLOGIES · Apr 10, 2025
Trial Information
Current as of July 27, 2025
Recruiting
Keywords
ClinConnect Summary
The Parent-Child EF Intervention trial is studying a new program designed to help young children, ages 2 to 5, develop important skills known as Executive Function (EF) skills. These skills include things like focusing attention, controlling impulses, and planning ahead, which are crucial for healthy development. The program uses a smartphone-based training designed for parents to engage with their children in fun and educational activities that support these skills.
To participate in this trial, children need to be between the ages of 2 and 5, and they must have a caregiver or guardian who can help. However, children with certain physical disabilities or severe developmental delays are not eligible. It’s also important that parents or caregivers can read and understand English. If selected, families can expect to take part in activities that can help their child grow and learn while having fun together. The trial is currently recruiting participants, so it's a great opportunity to be part of a program aimed at fostering healthy development in young children!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children ages 2-5 years.
- • Caregivers/guardian of the participating child.
- Exclusion Criteria:
- • Children with physical disabilities affecting vision, hearing, or basic mobility.
- • Children with severe developmental delays or disorders
- • Parents or caregivers who cannot read and understand English
About Koronis Biomedical Technologies
Koronis Biomedical Technologies is a pioneering clinical trial sponsor dedicated to advancing innovative therapeutic solutions in the biomedical field. Focused on developing cutting-edge treatments, the organization leverages state-of-the-art technology and rigorous scientific methodologies to conduct clinical trials that prioritize patient safety and efficacy. With a commitment to collaboration and transparency, Koronis Biomedical Technologies aims to accelerate the development of transformative therapies, ultimately improving health outcomes and enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Minneapolis, Minnesota, United States
New York, New York, United States
Patients applied
Trial Officials
Stephanie M. Carlson, PhD
Principal Investigator
University of Minnesota
Blair Hammond, MD
Principal Investigator
Mount Sinai General Pediatrics
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported